Amfetaminil: Difference between revisions
Content deleted Content added
No edit summary |
ArmbrustBot (talk | contribs) m →References: re-categorisation per CFDS, replaced: Category:Amphetamines → Category:Substituted amphetamines using AWB |
||
| Line 52: | Line 52: | ||
{{Phenethylamines}} |
{{Phenethylamines}} |
||
[[Category: |
[[Category:Substituted amphetamines]] |
||
[[Category:Nitriles]] |
[[Category:Nitriles]] |
||
[[Category:Norepinephrine-dopamine releasing agents]] |
[[Category:Norepinephrine-dopamine releasing agents]] |
||
Revision as of 13:56, 5 January 2015
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.037.767 |
| Chemical and physical data | |
| Formula | C17H18N2 |
| Molar mass | 250.338 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Amphetaminil (Aponeuron, AN-1) is a stimulant drug derived from amphetamine, which was developed in the 1970s and used for the treatment of obesity,[1] ADHD,[2][3] and narcolepsy.[4] It has largely been withdrawn from clinical use following problems with abuse.[5]
Stereochemistry
Amphetaminil is a molecule with two stereogenic centers. Thus, four different stereoisomers exist:
- (R)-2-[(R)-1-Phenylpropan-2-ylamino]-2-phenylacetonitrile (CAS-Nr. 478392-08-4)
- (S)-2-[(S)-1-Phenylpropan-2-ylamino]-2-phenylacetonitrile (CAS-Nr. 478392-12-0)
- (R)-2-[(S)-1-Phenylpropan-2-ylamino]-2-phenylacetonitrile (CAS-Nr. 478392-10-4)
- (S)-2-[(R)-1-Phenylpropan-2-ylamino]-2-phenylacetonitrile (CAS-Nr. 478392-14-2)
Synthesis
It is synthesized by forming the Schiff's base of amphetamine with benzaldehyde, and then nucleophilic attack on the latter with cyanide anion.[6]
References
- ^ Harris LS. The stimulants and hallucinogens under consideration: a brief overview of their chemistry and pharmacology. Drug and Alcohol Dependence 1986; 17:107.
- ^ Meyer-Probst B, Vehreschild T. Influencing the lack of concentration in hyperkinetic schoolchildren with Aponeuron. Psychiatrie, Neurologie und Medizinische Psychologie (Leipz) 1976; 28:491.
- ^ Paclt I, Florian J, Brunclikova J, Ruzickova I. Effect of Aponeuron in the treatment of children with hyperkinetic syndrome. (Czech). Ceska a Slovenska Psychiatrie. 1996 May;92 Suppl 1:41-57.
- ^ Schlesser JL. Drugs Available Abroad - A Guide to Therapeutic Drugs Approved Outside the US. MEDEX Books, Detroit, 1991.
- ^ Winter E. Drug abuse and dependence of the amphetamine type with special regard to Amphetaminil (Aponeuron(R)). (German). Psychiatrie, Neurologie und Medizinische Psychologie (Leipzig). 1976 Sep;28(9):513-25.
- ^ J. Klosa, DE 1112987 (1959); Chem. Abstr., 56: 3409d (1962).